Independent biomarkers, such as PD-L1 expression and TMB, are probably inadequately predictive in intratumoral immune microenvironments with heterogeneous features, and an integrated multiparameter evaluation will aid efforts to overcome within-tumor heterogeneity and identify patients who could derive the greatest therapeutic benefit.46 Based on the data from a 2018 pan-tumor study,47 the highest ORR and longest PFS were observed in patients with high PD-L1 expression and a high TMB. The gene discussed is CD274; the disease is neoplasm.